ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

PR firm Ketchum serves two clients on Medicare issues: CMS and ASCO. HHS policy officials weren’t told about potential conflict, department spokesman says.

September 24, 2004

SWOG Study To Test Predictive Value Of Circulating Tumor Cells In Breast Cancer

October 27, 2006

White House Seek Elimination Of NCI’s Bypass Budget Authority In Legislation Renewing Cancer Act

April 9, 1982

ACS Research Grants Hit $78.2 Million

July 18, 1986

Phase II Study Finds Dasatinib May Overcome ALL Resistance

May 25, 2007

NCAB Recommends Withdrawal Of CRCC Comprehensive Status

February 13, 1981